Recurrent bacterial vaginosis: Possibility of increasing the duration of remission
Objective. To investigate the efficiency and antirecurrent activity of adjuvant therapy with Multi-Gyn actigel for bacterial vaginosis (BV) in reproductive-aged women.Balan V.E., Tikhomirova E.V., Ovchinnikova V.V.
Subjects and methods. The investigation covered 50 female patients, whose mean age was 18 to 45 years (29.6±4.5 years), with a clinical diagnosis of BV confirmed by real-time polymerase chain reaction (Femoflor-16 real-time PCR).
The patients were randomized into two equal groups of 25 subjects in each. Group 1 received one-dose vaginal clindamycin cream overnight for 10 days and, as therapy stage 2, the actigel 2 mg twice daily for 10 days. Group 2 used one-dose vaginal clindamycin cream overnight for 10 days and, as therapy stage 2, a drug containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 for 14 days.
Results. The therapeutic effectiveness was 92% (n = 46) in both groups. However, the more sustained remission rates were 88% (n = 22) in the group of patients receiving adjuvant therapy with Multi-Gyn actigel and 64% (n = 16) in the comparison group (p < 0.5).
Conclusion. Long-term adjuvant Multi-Gyn actigel therapy in conjunction with etiotropic therapy was associated with a longer recurrent BV-free interval. Addition of Multi-Gyn actigel considerably improved treatment results. Drugs that contain probiotic Lactobacilli are also effective in the combination therapy of BV; however, their efficacy is based on their longer use.
Keywords
bacterial vaginosis
actigel
key cells
Supplementary Materials
- Table 1. General characteristics of surveyed patients
- Table 2. Schedule of research events
- Table 3. Dynamics of the effectiveness of treatment of bacterial vaginosis and duration of recurrence-free flow in groups
References
1. Kira E.F. Bacterial vaginosis. St. Petersburg; 2001. 364p. (in Russian)
2. Korshunov V.M., Volodin N.N., Efimov B.A. et al. Microecology of vagina. Correction of vaginal microflora at dysbacteriosis. Tutorial. Moscow: VUNMTS MoH; 1999. 80p. (in Russian)
3. Thomason J.L., Gelbard S.M., Scaglione N.J. Bacterial vaginosis: current rewiew with indications for asymptomatic therapy. Am. J. Obstet. Gynecol. 2001; 165(4): 1210-7.
4. Radzinskiy V.E., Tigieva A.V. Vulvovaginal disease: possible pathogenetic therapy. Effektivnaya farmakoterapiya. 2014; 4: 38-42. (in Russian)
5. Tapilskaya N.I., Karpeev S.A., Kuznetsova I.V. Chronic endometritis - subclinical inflammatory disease of the pelvic organs. Ginekologiya. 2014; 16(1): 104-9. (in Russian)
6. 1998 guidelines for treatment of sexually transmitted diseases. Centers for Disease Control and Prevention. MMWR Recomm. Rep. 1998; 47(RR-1): 1-111.
7. Wathne В., Hoist E., Hovelius B. Erytromycin versus metronidazolein the treatment of bacterial vaginosis. Acta Obstet. Gynecol. Scand. 1999; 72(6): 470-1.
8. Tyutyunnik V.L. Pathogenesis, diagnosis and treatment of bacterial vaginosis. Farmateka. 2005; 2: 20-4. (in Russian)
9. Malazy O.T., Shariat M., Heshmat R., Majlesi F., Alimohammadian M., Tabari N.K., Larijani B. Vulvovaginal candidiasis and its related factors in diabetic women. Taiwan J. Obstet. Gynecol. 2007; 46(4): 399-404.
10. Playford E.G., Sorrell T.C. Optimizing therapy for Candida infections. Semin. Respir. Crit. Care Med. 2007; 28(6): 678-88.
11. Witkin S.S. The vaginal microbiome, vaginal anti-microbial defence mechanisms and the clinical challenge of reducing infection-related preterm birth. BJOG. 2015; 122(2): 213-8.
12. Khosravi A.R., Eslami A.R., Shokri H., Kashanian M. Zataria multiflora cream for the treatment of acute vaginal candidiasis. Int. J. Gynaecol. Obstet. 2008; 101(2): 201-2.
13. Meizoso T., Rivera T., Fernández-Aceñero M.J., Mestre M.J., Garrido M., Garaulet C. Intrauterine candidiasis: report of four cases. Arch. Gynecol. Obstet. 2008; 278(2): 173-6.
14. Verboon-Maciolek M.A., Gerards L.J., Stoutenbeek P., van Loon A.M. Congenital infection: diagnostic serology of the mother not always definitive. Ned. Tijdschr. Geneeskd. 2001; 145(4): 153-6.
15. Sangkomkamhang U.S., Lumbiganon P., Prasertcharoensuk W., Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database Syst. Rev. 2015; (2): CD006178.
16. Guaschino S., De Seta F., Piccoli M., Maso G., Alberico S. Aetiology of preterm labour: bacterial vaginosis. BJOG. 2006; 113(Suppl. 3):46-51.
17. Nobile C.J., Mitchell A.P. Microbial biofilms: e pluribus unum. Curr. Biol. 2007;17(10): R349-53.
Received 16.12.2016
Accepted 23.12.2016
About the Authors
Balan Vera Efimovna, MD, professor, director of the outpatient department, Moscow Regional Research Institute of Obstetrics and Gynecology.101000, Russia, Moscow, Pokrovka str. 22a
Tikhomirova Elena Vladislavovna, PhD, the highest category doctor, researcher of Moscow Regional Research Institute of Obstetrics and Gynecology.
101000, Russia, Moscow, Pokrovka str. 22a. E-mail: heltik03@gmail.com
Ovchinnikova V.V., PhD, researcher of the outpatient department, Moscow Regional Research Institute of Obstetrics and Gynecology.
101000, Russia, Moscow, Pokrovka str. 22a
For citations: Balan V.E., Tikhomirova E.V., Ovchinnikova V.V. Recurrent bacterial vaginosis: Possibility of increasing the duration of remission.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (1): 83-8. (in Russian)
http://dx.doi.org/10.18565/aig.2017.1.83-8
Similar Articles
